Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026
Covered in this story
Call it yourself
No calls on $KTTA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pasithea Therapeutics →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.